Q-omics provides the consensus-scored FOXH1 profile across patient tissues and cancer cell-line models. FOXH1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FOXH1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, FOXH1 RNA expression shows 15,389 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where FOXH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXH1 survival associations across molecular data types. FOXH1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXH1 RNA expression–survival associations across cancer types. High FOXH1 expression shows unfavorable associations in ACC, KIRC, MESO, UVM and LIHC, but favorable associations in BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FOXH1 RNA expression.
This table summarizes FOXH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FOXH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXH1 shows lower tumor expression in COAD and higher tumor expression in KIRC, KIRP, LUSC, BLCA and UCEC. The KIRC box plot shows higher FOXH1 RNA expression in tumor versus normal tissue (log2 FC = +0.128, t-test p < 0.001).
This table shows molecular features associated with FOXH1 in patient tissues and cancer cell lines. In patient samples, FOXH1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
